Compare BNGO & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNGO | PASG |
|---|---|---|
| Founded | 2003 | 2017 |
| Country | United States | United States |
| Employees | N/A | 27 |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5M | 14.6M |
| IPO Year | 2018 | 2020 |
| Metric | BNGO | PASG |
|---|---|---|
| Price | $1.15 | $3.36 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | $5.00 | ★ $15.50 |
| AVG Volume (30 Days) | ★ 271.9K | 16.7K |
| Earning Date | 11-12-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.50 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,000,735.00 | N/A |
| Revenue This Year | $12.73 | N/A |
| Revenue Next Year | $34.74 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 26.26 | N/A |
| 52 Week Low | $1.00 | $3.29 |
| 52 Week High | $2.23 | $20.00 |
| Indicator | BNGO | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 32.20 | 34.46 |
| Support Level | $1.10 | $3.29 |
| Resistance Level | $1.19 | $4.92 |
| Average True Range (ATR) | 0.08 | 0.35 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 13.75 | 1.07 |
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.